Highlights

  • Cogstate (ASX:CGS) reported FY26 revenue of US$60.9 million, an increase of 15%.
  • Net Clinical Trials sales contracts reached US$89.0 million in FY26, up 116%.
  • FY26 EBITDA was US$18.3 million; year-end cash totalled US$34.8 million.
  • Active clinical trials increased to 171 by 30 June 2026.

Cogstate Limited (ASX:CGS) develops digital cognitive assessments and clinical-trial measurement services for pharmaceutical research and healthcare providers. Its latest FY26 results describe increased contracting activity, broader clinical-trial coverage and investment in AI-enabled operations. During trading on 20 October 2026, Cogstate shares were quoted at AUD 3.52, down 0.28% on the session. That market movement is separate from the company's August financial disclosures and does not establish a cause for the change in price.

Company Business

Cogstate supplies computerised tests that measure memory, attention and other cognitive functions. Its clinical-trials work includes digital assessments, electronic clinical outcome assessment support, scientific consulting, rater training and monitoring of endpoint data. Customers use these services to measure cognition and manage assessment consistency during studies of investigational medicines.

Through healthcare-facing products, Cogstate (ASX:CGS) also supports screening and monitoring of cognitive change. Its official website describes the Lila memory app for individual-led tracking and Cognigram for clinician-supported assessments. The business serves international research programmes, with operations spanning trial sites and remote testing arrangements. Revenue is generated principally from clinical-trial services rather than consumer screening products.

Recent Development

In August 2026, Cogstate disclosed US$89.0 million in net Clinical Trials sales contracts for FY26, compared with US$41.3 million a year earlier. The company reported 171 active trials at 30 June 2026, up from 110 at the start of the financial year. Its new contract mix included rare disease, psychiatric and mood disorders, Alzheimer's disease, sleep conditions and other neurological indications.

Cogstate (ASX:CGS) is expanding automation within its trial delivery systems. According to its FY26 release, AI-enabled rater training and central monitoring had entered its toolkit, while a further operating-platform programme is planned across FY27 and FY28. The company has described the programme as intended to coordinate workflows, reduce manual tasks and support consistent oversight; realised cost and productivity outcomes remain to be established.

Separately, Cogstate announced in August 2026 that it would supply cognitive performance measurement for the XPRIZE Healthspan competition. The involvement concerns measurement services, not evidence of a new therapeutic product approval or a forecast of contract revenue.

Financial Performance and Sector Context

For the year ended 30 June 2026, Cogstate (ASX:CGS) reported group revenue of US$60.9 million against US$53.1 million in FY25. Clinical Trials revenue was US$58.4 million, while Healthcare revenue was approximately US$2.5 million. The company's financial release reported gross profit of US$35.4 million and a 58% gross margin, compared with 61% in FY25.

EBITDA rose to US$18.3 million from US$16.0 million, with the EBITDA margin remaining 30%. EBIT reached US$15.2 million and profit after tax was US$11.9 million. Operating cash inflow totalled US$8.5 million, while the 30 June cash balance was US$34.8 million, with no debt disclosed in the results announcement.

Clinical research contracts can involve lengthy study schedules, protocol changes and variable timing of service delivery. This makes the conversion of new sales contracts into recognised revenue an important operating measure. Cogstate's disclosed gross margin decline also illustrates how delivery staffing, commissions and technology investment affect profitability despite higher activity volumes.

Risks to Consider

For Cogstate (ASX:CGS), financial outcomes depend partly on trial starts, recruitment progress, sponsor decisions and the timing of contracted research work. Studies may be delayed, scaled back or discontinued, affecting the pace of revenue recognition. The growing trial portfolio also requires trained personnel, secure systems and reliable data-quality processes.

The multi-year automation programme involves implementation and capital-allocation risks. Spending may occur before anticipated efficiency benefits materialise. Regulatory expectations for clinical-trial data integrity, cybersecurity and privacy remain relevant when cognitive measurements are collected across multiple jurisdictions and remote settings.

What to Watch Next

Cogstate reported contracted future revenue of US$118.5 million entering FY27, including US$48.3 million expected to be recognised during that year. These are company-reported expectations, not guaranteed receipts. Investors can compare subsequent contracting updates with the rate of service delivery, cash collection and revenue recognition.

Other identifiable monitoring points include delivery of the FY27–FY28 technology programme, clinical-trial activity levels and changes in gross margin. Cogstate said its FY27 financial profile was expected to be weighted toward the June 2027 half-year; later filings will show whether operational results follow that timetable.

Key Insights

Cogstate (ASX:CGS) entered FY27 after reporting higher FY26 revenue, contracting activity and EBITDA, alongside a debt-free year-end cash position. Its main business remains clinical-trial cognitive measurement, complemented by healthcare assessment tools. Contract conversion, operating costs and execution of the automation plan will provide measurable context for future results, rather than the daily change in its share price.